Cargando…
Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
BACKGROUND: Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic buffer....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818778/ https://www.ncbi.nlm.nih.gov/pubmed/29497674 http://dx.doi.org/10.1186/s40981-016-0046-5 |